Welcome to first recruited patient for HOOKIPA

We are pleased that Dr Chris Hill, co-lead NICRN renal group, has recruited the first patient to the H-100-102 Hookipa study:
“A Randomised, Placebo-controlled Phase 2 study of HB-101, Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient 9R-) Patients Awaiting Kidney Transplantation from Living CMV – Seropositive Donors (D+)”
Read more about the study here
Share
Latest News
- Support the COVID Rehabilitation Fund23 April, 2020
- Job Opportunity, NICRF: Band 6, BHSCT post2 January, 2020
- Happy New Year from NICRF2 January, 2020
- Welcome to the first participants of the VR_LV Study, November 201811 December, 2018
- Welcome to the first participants of the MACUSTAR Study, January 20194 December, 2018